• FY27 financial guidance: The company targets consolidated revenue of ₹2,300–2,400 crore, with ₹1,900–2,000 crore coming from India at a 26–27% EBITDA margin and ~₹400 crore from acquired international businesses at an 11–12% margin. Standalone EBITDA margins are projected at 26–28%, while consolidated margins are expected to range between 24% and 25%.
• Renal segment investigation: Amid pricing pressure from Chinese and Malaysian competitors, an anti-dumping investigation has been initiated, with the company seeking government protection against an estimated 20% injury margin to support domestic self-reliance.
• Middle East shipping disruptions: Supply chain and shipping route bottlenecks to West Asia and the Middle East have caused a 2–3% hit to top-line growth, despite healthy order books in these markets, which account for 6–7% of exports.
• Acquisition integration strategy: Full margin synergies from recent acquisitions like Plan 1 Health, Pendra Care, and GDFE will take 2–3 years due to regulatory recertification while production transitions to India. Future M&A will focus on expanding direct market presence and adjacent technologies in cardiology, orthopedics, and oncology.